Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP

K. K. Wong, E. S. Ch'ng, S. K. Loo, A. Husin, M. A. Muruzabal, M. B. Moller, Lars Møller Pedersen, M. P. Pomposo, A. Gaafar, A. H. Banham, T. M. Green, C. H. Lawrie

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Huntingtin-interacting protein 1-related (HIP1R) is an endocytic protein involved in receptor trafficking, including regulating cell surface expression of receptor tyrosine kinases. We have previously shown that low HIP1R protein expression was associated with poorer survival in diffuse large B-cell lymphoma (DLBCL) patients from Denmark treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In this multicenter study, we extend these findings and validate the prognostic and subtyping utility of HIP1R expression at both transcript and protein level. Using data mining on three independent transcriptomic datasets of DLBCL, HIP1R transcript was preferentially expressed in germinal center B-cell (GCB)-like DLBCL subtype (P<0.01 in all three datasets), and lower expression was correlated with worse overall survival (OS; P<0.01) and progression-free survival (PFS; P<0.05) in a microarray-profiled DLBCL dataset. At the protein level examined by immunohistochemistry, HIP1R expression at 30% cut-off was associated with GCB-DLBCL molecular subtype (P=0.0004; n=42), and predictive of OS (P=0.0006) and PFS (P=0.0230) in de novo DLBCL patients treated with R-CHOP (n=73). Cases with high FOXP1 and low HIP1R expression frequency (FOXP1 hi/HIP1R lo phenotype) exhibited poorer OS (P=0.0038) and PFS (P=0.0134). Multivariate analysis showed that HIP1R<30% or FOXP1 hi/HIP1R lo subgroup of patients exhibited inferior OS and PFS (P<0.05) independently of the International Prognostic Index. We conclude that HIP1R expression is strongly indicative of survival when utilized on its own or in combination with FOXP1, and the molecule is potentially applicable for subtyping of DLBCL cases.

Original languageEnglish
JournalExperimental and Molecular Pathology
Volume99
Issue number3
Pages (from-to)537-545
ISSN0014-4800
DOIs
Publication statusPublished - Dec 2015

Keywords

  • Diffuse large B-cell lymphoma
  • HIP1R
  • Subtyping
  • Survival
  • Immunohistochemistry
  • Prognosis
  • Area Under Curve
  • Tissue Array Analysis
  • Humans
  • Middle Aged
  • Male
  • Doxorubicin
  • Young Adult
  • Biomarkers, Tumor/analysis
  • Sensitivity and Specificity
  • Aged, 80 and over
  • Adult
  • Female
  • Antibodies, Monoclonal, Murine-Derived
  • Kaplan-Meier Estimate
  • Antineoplastic Combined Chemotherapy Protocols
  • Rituximab
  • Prednisone
  • Vincristine
  • Disease-Free Survival
  • Cyclophosphamide
  • Lymphoma, Large B-Cell, Diffuse/drug therapy
  • Vesicular Transport Proteins/analysis
  • RNA, Messenger/analysis
  • ROC Curve
  • Aged

Fingerprint

Dive into the research topics of 'Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP'. Together they form a unique fingerprint.

Cite this